So you want to become a biotech CEO

Jan 17 2003
At the Second Annual Biotechnology and Pharmaceutical Conference, Dan Eramian

Pennsylvania Biotechnology Association

Jan 16 2003
Carl B. Feldbaum

MMA Legislative Text

Jan 7 2003

Full Text of the Medicare Modernization Act, Medicare Prescription Drug and Modernization Act of 2003, Public Law 108-173

Comments on Draft OIG Compliance Guidance

Dec 2 2002

For Pharmaceutical Manufacturers

Letter, Concerns with Trade-Related Aspects of Intellectual Property (TRIPS)

Nov 27 2002

Letter to The Honorable Robert Zoellick, US Trade Representative

BIO supports limited liability protection

Nov 18 2002
Letter to the Senate opposing an amendment to strike provisions in the Department of Homeland Security Act of 2002 that would provide limited liability protection for the production of antiterrorism countermeasures, vaccines, and therapeutics.

Court Decision Invalidating FDA's Pediatric Rule

Nov 14 2002


Bioterrorism: A Challenge We Cannot Decline to Meet

Nov 6 2002
Carl B. Feldbaum, BIO President (Nov. 6, 2002).

Letter on the PTO's strategic plan and their fee restructuring proposal

Oct 24 2002
We are writing to express our support for the efforts of the United States Patent and Trademark Office (USPTO) to address the crisis situation facing the patent and trademark systems.

FDA Letter Opposing Oregon Measure 27

Oct 4 2002
This letter explains why FDA objects to the pending ballot initiative to require the mandatory labeling of foods and food additives produced using genetic engineering sold in Oregon, or produced in Oregon and shipped to other states. In brief, FDA's scientific judgement is that there is no significant difference between foods produced using bioengineering, as a class, and their conventional counterparts.